Tom Spurling – Executive Director – Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
Copyright 2023 – Finance News Network
Source: Finance News Network
22 Jun 2023 - Lake Resources Limited (ASX:LKE) Managing Director David Dickson discusses the company's two-phase strategy.
Read More19 Jun 2023 - Industry standard graphite anodes have reached their technical limitations. AnteoTech Limited (ASX:ADO) CEO and Managing Director David Radford discusses the company's solution for significantly increasing battery capacity by enhancing silicon integration.
Read More16 Dec 2019 - Openpay Group (ASX:OPY) CEO & MD, Michael Eidel talks about its business model, size of the opportunity and how it differentiates itself from other buy now pay later (BNPL) providers.
Read More31 May 2023 - Ron Mitchell, Managing Director of Global Lithium Resources Limited (ASX:GL1), which owns two of the 14 lithium resources in Australia, discusses the price of lithium and progress on the company's projects.
Read More29 Mar 2021 - XTEK Limited (ASX:XTE) Managing Director Phillipe Odouard talks 1H21 results, discussing the company's expanded operational capacity to meet demand for its high-value proprietary solutions in a favourable market environment for domestic and global defence industries.
Read More11 Aug 2020 - Regeneus (ASX:RGS) CEO, Leo Lee talks about its collaboration with Kyocera of Japan to market Progenza its cell therapy treatment for anti-inflammatory treatment and repair of damaged or diseased tissue.
Read More12 Apr 2023 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun discusses recent results, strategy, opportunities post lockdown and milestones ahead.
Read More29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.
Read More29 Nov 2023 - Equinox Resources Limited (ASX:EQN) CEO Zac Komur discusses the company's move to apply for a large rare earths tenement in Brazil, and the attractions of the jurisdiction.
Read More
